Le Lézard
Classified in: Health
Subjects: PDT, PLW

New U.S. Patents Granted for RegenLab


LE-MONT-SUR LAUSANNE, Switzerland, September 13, 2018 /PRNewswire/ --

Mr. Antoine Turzi, inventor, Regen Lab SA and RegenLab USA LLC are delighted to announce that the United States Patent and Trademark Office (USPTO) has issued two new U.S. patents covering its Platelet Rich Plasma (PRP), Bone Marrow Concentrate (BMC) and Hyaluronic Acid (HA) technologies:

  1. Systems/methods combining PRP and HA: U.S. Patent No. 10,052,349 and
  2. Systems for the preparation of PRP and BMC, in particular tubes containing a thixotropic gel and anticoagulant: U.S. Patent No. 10,064,894.

This brings a total of six U.S. granted patents with US8,529,957, US9,833,478, US9833478, US8,945,537 and US9,517,255 on these technologies, expanding RegenLab's patent portfolio along with patents also recently granted in other jurisdictions (see figure below).

     (Photo: https://mma.prnewswire.com/media/743261/RegenLab_Figure_1.jpg )

     (Logo: https://mma.prnewswire.com/media/743260/RegenLab_Logo.jpg )

All these new patents represent a recognition by the USPTO of RegenLab's innovation, technology and efficiency. This is great news for RegenLab, its employees and partners, and justifies that RegenLab maintains its legal actions for the respect of its intellectual property rights. The stars are shining for RegenLab's team and its future.

About RegenLab 

RegenLab is a leading innovator of medical devices for the preparation of platelet rich plasma, which it markets under the well-recognized REGENLAB® and REGENKIT® brands. RegenLab remains committed to providing pyrogen-free devices of the highest quality and safety, as well as protecting customers through enforcement of its intellectual property rights.

Additional information about RegenLab and its patents can be found at https://www.regenlab.com/patents and http://www.RegenLabUSA.com.


These press releases may also interest you

at 05:12
Sobi establishes MTN programme with a framework amount of SEK 10 billion, publishes a base prospectus
Swedish Orphan Biovitrum AB (publ) (Sobi®) has established a medium term note programme with a framework amount of SEK 10 billion or the equivalent thereof in EUR (the "MTN Programme"). For this purpose, Sobi has prepared a base prospectus, which...

at 04:00
OMRON Donates Some 3,200 Units of Blood Pressure Monitors to Global Blood Pressure Screening Campaign on World Hypertension Day
OMRON Healthcare Co., Ltd. based in Muko, Kyoto Prefecture, Japan, announces to be the official sponsor of May Measurement Month (MMM,) a global campaign to raise awareness of blood pressure screening and promote hypertension prevention, detection,...

at 02:48
RaySearch publishes Annual Report for 2023
Today, RaySearch Laboratories AB (publ)  publishes its Annual Report for the financial year 2023. The report is held available on RaySearch's website, under the section Investors.  This information is information that RaySearch Larboratiories AB...

at 02:43
ZINZINO AB (PUBL): NOTICE OF ANNUAL GENERAL MEETING IN ZINZINO AB ON MAY 27, 2024
Shareholders of Zinzino AB (publ) are hereby invited to the annual general meeting on Monday, May 27, 2024, at 1:30 PM at the company's premises at Hulda Mellgrens gata 5 in Gothenburg. Registration begins at 1:15 PM. The company aims to webcast the...

at 02:41
Implantica publishes Annual Report 2023
Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, is publishing its annual report for the fiscal year 2023. The annual report is now available on the company's website. "Implantica had a very...

at 02:08
Interim report January-March 2024: Medicover
Revenue amounted to ?498.8m (?419.3m), an increase of 18.9% with an organic growth of 14.2%.Operating profit (EBIT) was ?19.0m (?10.7m), an increase of 78.0%, representing an operating margin of 3.8% (2.6%).Net profit amounted to ?6.5m (?2.1m), which...

More news about Health...


News published on and distributed by: